StemCell Therapy

Colorado ranchers and farmers have serious doubts about one new member of the State Board of Veterinary Medicine

They are asking Governor Polis to reconsider his selection of Ellen Kessler to the veterinary boards public at large position.

Rancher and Fencepost.com assistant editor Rachel Gabel says Ellen Kessler is a self-proclaimed animal rights activist. Her social media posts include claims that she is Vegan, Extreme" and "Annoying.

And Gabel tells Colorado Ag Today, Kessler hit a nerve in the community when she recently posted on social media that, 4-H clubs teach children that animal lives dont matter.

Gabel: Its not about whether she decided to have plant-based protein or if she likes or doesnt like 4H. What this is about is protecting our large animal veterinarians and our food animal veterinarians that are vitally important to agriculture here in Colorado. They are hard to find. A good vet out here is hard to find. Were facing a veterinary shortage and we have one of the top veterinary colleges in the country. We certainly dont want to do anything that might cause our veterinarians to look for another state in which to practice.

Appointees will serve until their respective confirmation hearings during the next legislative session beginning in January.

Gabel has written a letter to the Governor asking that Ellen Kesslers appointment be retracted prior to her confirmation hearing. The Colorado Livestock Association has also written a letter and supports a petition seeking Kessler's removal from the board.

A message to Kessler from Colorado Ag Today for comment has not been answered.

See the article here:
Agriculture Opposes State Vet Board Selection - AG INFORMATION NETWORK OF THE WEST - AGInfo Ag Information Network Of The West

Job Description

The Department of Veterinary Medicine is part of the College of Food Agriculture & Veterinary Medicine and is the only Bachelor of Veterinary Medicine degree granting body in UAE. The program was launched in 2013-2014 and it has graduated two cohorts of UAE nationals (total 38 veterinarians). Presently, the non-clinical education is taught in the UAE and the clinical education/training is conducted in collaboration with University of Veterinary Medicine, Budapest (UVMB). The vision of UAEU is to establish a full-fledged College of Veterinary Medicine. As of October 2020, the department will move to a new campus with 9 new laboratories, faculty and staff offices and associated facilities, and will soon offer para-clinical programs. Today, the department includes 11 full-time faculty and three adjunct faculty members and offers basic and para-clinical veterinary medical education. The Department of Veterinary Medicine is fortunate to have an outstanding faculty, all of whom hold a doctor of veterinary medicine degree and/or a PhD and research experience. UAEU embraces diversity and inclusion and many of the faculty members, particularly in the Department of Veterinary Medicine, come from culturally diverse backgrounds and bring international best practice. The Department of Veterinary Medicine is acknowledged nationally for the uniqueness of the BVM program offered in the country.

Minimum Qualification

UAEU seeks an individual with a record of distinguished academic achievement and leadership who can thrive in a start-up environment. Clinical experience is preferred and 2-3 years of administrative experience is essential. Key to the success of the Departments vision and mission is the ability to attract and develop the best talent, expand the current program, introduce a Postgraduate program, develop new clinical laboratories and research centers, and evolve the department into a full-fledged independent unit in the near future. The successful candidate will provide strong leadership, be an advocate for the department, and its faculty, staff, and students within the university community and beyond and provide vision for future development. Reporting to and working with the Dean of College of Food Agriculture & Veterinary Medicine, the Chair must be able to work across disciplinary boundaries. The ideal candidate will demonstrate commitment to recruitment, retention, and placement of a diverse group of students, faculty and staff.

Preferred Qualification

An earned Doctorate in Veterinary Medicine from an accredited institution with outstanding scholarly accomplishments; and ability to meet standards for appointment at the rank of professor in an academic department of the university. Furthermore, the ideal candidate should have a proven track record of teaching and research, an understanding of veterinary education and its management, and a keen desire to incrementally build the department by adding new dimensions each year to its profile. The successful candidate should have the ability to shape and energetically lead a diverse and expanding Department, a record of faculty mentorship and development, excellent interpersonal and group communications skills, and administrative abilities.

Expected Skills/Rank/Experience

Professor; Management experience 2-5 years Desired experience and qualifications will include:

Special Instructions to Applicant

Informal enquiries may be made to Prof Bhanu Chowdhary (Dean of College of Food, Agriculture and Veterinary Medicine) - bchowdhary@uaeu.ac.ae

Division College of Food & Agriculture-(CFA)

Department Veterinary Medicine - (CFA)

Job Close Date open until filled

Job Category Management

Salary 0 to 833333.25 AED

Here is the original post:
Chair job with UNITED ARAB EMIRATES UNIVERSITY | 219153 - Times Higher Education (THE)

Trained responders from The Marine Mammal Centers Monterey Bay Operations prepare to attempt a boat rescue of an injured California sea lion at the Monterey Coast Guard Pier in Monterey, CA. To learn more about the Center and how to support the recovery of patients suffering from entanglements, text OCEAN to 41444 to donate or visit MarineMammalCenter.org/donate. Credit The Marine Mammal Center

| FEATURED

By Kyle Martin

As Central Coast residents mitigate the threat of COVID-19, a cadre of local scientists working on marine mammal research has been undeterred in their quest. And the U.S. government has taken a liking to their efforts to find out more.

But COVID has shuttered a lot of research possibilities as well as the labs in which those scientists need to do their work. Since the start of the pandemic, research opportunities on the waters of the Monterey Bay Marine Sanctuary and elsewhere have been changed, rescheduled or shut down.

In efforts to keep its volunteers and staff safe from COVID infection, the Marine Mammal Center has stopped many of their rescue missions to save animals in and around Monterey Bay.

Even so, there are a few new unique scientific research opportunities that have opened up now that humankinds influence on the world has been muted.

Enlarge

COVID strikes

On April 27, Dr. Ari Friedlaender and Dr. Caroline Casey, a married couple of marine scientists with extensive research backgrounds, along with Julia OHern, manager of the Marine Mammal Center in Moss Landing, were able to find a way out onto the sea as they navigated the precautions that come along with COVID.

Local COVID orders have closed off much of the usual water access, and many boats havent been able to set sail, resulting in fewer marine researchers actually being able to get to where they need to go to do research.

Everything sort of got put on hold, in terms of being able to go out on the water and do work out there, Casey said. Once lockdown hit, basically all field work was halted for almost everybody.

Its also been problematic for marine mammal rescue. OHern said sea lions pups get stranded in significantly high numbers during the summer and this is typically the Marine Mammal Centers busiest time of year.

Its a little nerve-wracking to sort of come up with a new plan and adapt old plans very quickly, OHern said. Its a unique human health crisis in the sense that we typically deal with animal health crises.

I guess we were fortunate in the sense that having this kind of preparedness for unique and challenging situations is something that we have to do, and that we train folks to do. But of course, something like what were going through right now is definitely not anything that I had on my radar.

In May, a joint rescue effort between the Marine Mammal Center and the U.S. Coast Guard saved a humpback whale tangled in crab fishing gear in Monterey Bay, but plenty of other calls about lost or stranded animals have gone unchecked because of pandemic restrictions.

In the very beginning, the biggest decision we had to make was, Were we essential? said Dr. Shawn Johnson, vice president of veterinary medicine and science at the Marine Mammal Center. We clearly felt that rescuing animals was a public service that we were providing. And were a veterinary hospital, which is an essential service.

Johnson said they decided as veterinarians operating a veterinary hospital, yes, they were essential. But as marine animal rescuers and researchers, not necessarily. Not all the time. Not if it was ultimately more dangerous to humanity by threat of COVID outbreak.

Its hindered our ability to mount rescue responses to the beaches and get access to the beaches and, to be honest, a lot of our volunteers arent comfortable going out into the public and being surrounded by a bunch of people on the beach who may not be socially distancing and wearing a mask, Johnson said.

While the Marine Mammal Center is normally equipped with plenty of personal protective equipment, sanitizer, masks and other medical materials for its veterinary staff, many closed-quarters rescue missions just couldnt happen.

But meanwhile, Friedlaender came up with some plans for the future and asked Johnson, OHern, Casey and other scientists around Monterey for help. Together, they began sampling blubber in humpback whales in Monterey Bay.

Enlarge

A new idea

We need to go out and do this, Friedlaender said, recalling a conversation he had early on about taking samples from Monterey Bay whales. I dont care if we dont have money, we just need to do it.

Friedlaender and Casey connected with OHern and the Marine Mammal Center to get a small vessel on the water socially distanced, of course. Armed with a crossbow-like device to collect blubber samples from the giant marine mammals, the group spent five days collecting dozens of samples, which are now stored and ready to be analyzed.

Theyre trying to determine whether humpback whales coming through the bay have higher cortisol levels a stress hormone during periods of high human noise and boat traffic, versus right now without as much noise and traffic.

Or, more simply, if whales are more stressed because of us.

This is important for a lot of reasons, Friedlaender said. The fact that humans influence almost every environment and every ecosystem on the planet and we are all over the place. And we are polluting with noise, were polluting with chemicals, were polluting in all sorts of ways and extracting and changing systems. And we very rarely have an opportunity to think about, let alone quantify, what impact were having on these systems.

Casey said that unlike other creatures stressed by their environment, whales have fewer options to move away from the source of their distress. Their favorite feeding grounds are in the Monterey Bay Marine Sanctuary, so in order to get food, they have to come here and endure human commotion.

Amazingly, if you leave them alone, they have the opportunity to rebound, Casey said. We want to keep that happening.

Whales are a really great representative for, not only the health and wellness of the marine ecosystems, but they also are the sentinels for being able to tell us how much stress we as humans are putting on the environment, Friedlaender said. And so, with all the bad things that this pandemic has done to affect humans, its relieved some pressures on animals and ecosystems in ways that are likely to give them a little bit of a breath some breathing room.

It wasnt all that long ago that whale populations were traumatized and decimated by whaling along the Pacific Coast and elsewhere. Even just two years ago, California recorded the highest number of whale deaths by ship collision since the 1980s, according to the Washington Post, after a humpback was killed by a freight container ship coming into San Francisco.

Enlarge

The Way Forward

Immediately after their April sampling, Friedlaender said he pitched the National Science Foundation on a grant to fund the project. He got notice at the end of June the NSF is planning to take them up on their research and award them more than $100,000 this month to continue their studies.

This will pay for researchers to analyze data, another ship and crew to go out and sample whales again during the same time period next year, and plenty of other gear and logistics costs. This includes help from the Monterey Bay Aquarium Research Institute (MBARI), which has gear such as hydrophones, and expertise to gather and analyze acoustic samples in the water to show human and boat noise reduction throughout the ocean.

In partnership with the Marine Mammal Center, the University of California, Santa Cruz, MBARI and the California Ocean Alliance, a new team of marine researchers and ocean stewards hoping to take on major exploits into the worlds waters, there will be new, real-time data proving the impact of human activity on whale populations.

Have something to say about this story? Send us a letter.

SUPPORT NONPROFIT JOURNALISM

GET OUR FREE WEEKLY NEWSLETTER

View original post here:
Setbacks and opportunities Voices of Monterey Bay - Voices of Monterey Bay

Animal behaviour scientists from the University of Lincoln, UK, have discovered that filling your home with appeasing pheromones could be the key to a happy household where both dogs and cats are living under the same roof.

The new research, led by Professor Daniel Mills and Dr Miriam Prior, explored the effects of two different pheromone products on cat-dog interactions in homes where owners could see room for improvement in their pets' relationships.

Their new scientific paper is now available to read online via the journalFrontiers in Veterinary Science.

The results show that both products used - One product emits pheromones that are calming for cats, and another does the same for dogs - both had a positive impact on the interactions between cats and dogs living in the same home.

Over a six week period, both products led to a notable decrease in undesirable interactions - such as dog chasing cat, cat hiding from dog, cat and dog staring at each other, and dog barking at cat. Users of Adaptil even observed a significant increase in some desirable behaviours - friendly greetings between cat and dog, and time spent relaxing in the same room.

"Although we are all aware of the perceived tensions between cats and dogs, we believe this is the first study of its kind to explore the use of pheromone products to improve the relationship when the two species are living in the same household," explained Professor Mills, Professor of Veterinary Behavioural Medicine in Lincoln's School of Life Sciences.

It has also been reported that a problematic relationship between a new pet and an existing pet is one of the main reasons for cats and dogs being taken to shelters for rehoming.

"Seven per cent of households in the UK own both a cat and a dog, which represents a large number of pet owners and their animals living with potentially stressful animal relationships on a day-to-day basis. Many cat and dog owners report that their animals are comfortable in each other's' company, but where this isn't the case, a poor relationship between a resident cat and dog can have serious consequences for the welfare of individual animals. There may be an unacceptable level of social stress or restricted access to key resources such as food, water or suitable toilet areas. There will also be increased stress for the remainder of the family (both human and animal), and potential risks of injury due to conflict."

The pet owners involved in this new scientific trial reported weekly on the frequency of 10 specific undesirable interactions and seven specific desirable interactions between their cats and dogs. They were split into two groups; one group using a feline pheromone product and the other using dog pheromones, with the pheromones supplied in unlabelled packaging and randomly assigned by an independent staff member such that neither the participants nor the researchers knew which product was being trialled in each household until after the statistics had been collected.

The researchers were aware that in many households, the comfortability of the cat seems to have a stronger influence over the quality of the cat-dog relationship. It could therefore be seen as surprising that it was the product releasing dog pheromones which was seen to increase specific desirable interactions.

Miriam, a Lincoln-based vet who undertook the work as part of her postgraduate degree in Clinical Animal Behaviour at the University of Lincoln, said: "While it might be expected that pheromones would be more effective in multi-species homes given the apparently stronger contribution of the cat's comfortability to the quality of the cat-dog relationship, this did not appear to be the case. Our results might be explained by the behaviour of the dog being the primary determinant of the cat's quality of interaction with it.

"We would like to investigate this further to really tease out the effects of these pheromone products individually and also to investigate their use in combination with each other. We suggest that Adaptil may have had such a beneficial effect because a more relaxed dog may be less likely to disturb the cat (e.g. by chasing it), resulting in a cat that is less stressed and more willing to form some form of social bond with the dog."

See the article here:
Scientists reveal pheromones are key to harmonious pet relationships - Jill Lopez

Veterinarians, whether specializing in large or small animals, deal with stress under the best circumstances. But in this time of difficult decisions for pork producers and those who service them due to COVID-19, maintaining mental health is even more of a concern, Athena Diesch-Chham told Pig Health Today. The veterinary social worker in the Veterinary Medical Center, College of Veterinary Medicine at the University of Minnesota said mental health has been a taboo subject for far too long, noting that the quickest way to break that stigma is for everybody to join in the conversation. This is a population that has held that off for a very long time.

Statistics on veterinary mental health shocked the veterinary profession when they were released about 6 years ago. The numbers were alarmingly high, but some people remained in denial.

I remember the first conference I ever went to, Diesch-Chham recalled. I actually had a large-animal veterinarian tell me, This is a small-animal problem. We dont have this in large-animal practices.

When the American Association of Swine Veterinarians reached out to Diesch-Chham to speak to swine veterinarians, it was evident to her that the topic couldnt be ignored. Thankfully, the response has been positive. Swine veterinarians are getting into the conversation and are talking about what they can do to deal with stress.

A number of factors contribute to stress, but in reality, veterinarians are part of an unsustainable model, Diesch-Chham said. The high debt and isolation are part of being a large-animal veterinarian because their practices are primarily situated in rural areas. Other characteristics of the profession have existed for a long time, too.

We could talk about the old standard of veterinary medicine, where you work 100 hours a week, you are on call all the time, you are the lifeline for producers, you dont take vacations and you dont say no, Diesch-Chham said. You give, you give and you give, and thats not sustainable.

Large-animal veterinarians who have reached retirement age are having a hard time finding people to take over their practices, Diesch-Chham said. They want to blame it on a poor work ethic by the younger generations, but its more a matter of sustainability, she added, noting the model hasnt been sustainable for decades.

Veterinarians go into the profession because they love animals. The individuals select this profession somewhere between the ages of 5 and 8, and then build the rest of their lives around becoming a veterinarian, Diesch-Chham said.

They have a built-in caretaker genome from early on, she said. That caretaker gene makes it really hard for [veterinarians] to say, No, she added.

It also makes it difficult for them to allow time for themselves. The empathy they have for the animals in their care as well as for the farmers with whom they work overrides their personal wellness at times.

Veterinarians have feelings, and in veterinary medicine we do not teach people how to manage those feelings, Diesch-Chham said.

Diesch-Chham pointed out that not all stress is bad. In fact, manageable stress can help people reach levels of peak performance.

Thats when we are doing great things, but most of us cannot acknowledge and/or have no awareness of where the line is [between positive and negative stress], she said. Almost all of us push ourselves over the curve, and that is when we start to see the signs of burnout.

When that burnout goes on for a long time, it has, in the past, been called compassion fatigue but Diesch-Chham and others in the veterinary mental-health profession refer to it as moral distress.

Moral distress is about going too far for too long with situations that may or may not sit perfectly within your moral compass, Diesch-Chham said. If we think about veterinary medicine and how often that happens how often they are told they dont have the autonomy to say no to certain situations we get to moral distress.

Diesch-Chham first heard about moral distress and moral injury about 5 years ago and feels research on the topic has come a long way since that time.

Its awesome to see mental-health professionals studying it and applying it to veterinarians, she said. I have never met a veterinarian who stopped caring, and I would hypothesize that they care too much for too long.

When you ask someone how theyre doing, listen to their answer, Diesch-Chham said. If they say, Im okay, or Im fine, stop right there. Those are canned answers.

That means the individual is probably not okay. It may mean he/she doesnt want to discuss details or doesnt know if its safe to discuss details with you, Diesch-Chham explained. Dig deeper, she said. Make eye contact and show genuine concern so the individual will share with you how he or she is really feeling, she said.

Veterinarians may serve as a first line of defense for producers who are struggling with stress, too.

My dad is a producer, so Ive watched a lot of this my whole life, Diesch-Chham said. When things are going well, she sees how he interacts with his veterinarian and producer friends. She also sees what happens when the market tanks or when disease hits.

Changes within veterinary medicine need to occur, and awareness of those around us needs to improve, starting with active listening and picking up on cues.

If a veterinarian walked on my farm and said, Hey, how is your family? [he or she] might find out way more about the stressors going on in that farm or in that family than any other conversation, she said.

The same is true for veterinarians: Its important for them to communicate and go beyond surface pleasantries when they talk with peers and loved ones.

Diesch-Chham encouraged veterinarians who experience moral distress to reach out to their mental-health community.

You cant pull anybody else out of the stream if youre in it too, she said. We need to get veterinarians to a better place. Pull yourself out of the stream so you can help all of us on the banks pull people out who need help.

See the article here:
Veterinarians, mind your mental health - The Pig Site

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.

AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem), for ImStem to utilize AgeXs ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.

We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology, said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.

AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.

AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far, said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.

Q2 Highlights

Liquidity and Capital Resources

AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescences discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.

On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.

Staff Reductions

In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeXs strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.

Going Concern Considerations

As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeXs most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescences discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeXs Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.

Second Quarter 2020 Operating Results

Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.

Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.

General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeXs own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeXs core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeXs Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

AGEX THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)

June 30,2020

December 31,2019

(Unaudited)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

1,033

$

2,352

Accounts and grants receivable, net

235

363

Prepaid expenses and other current assets

836

1,339

Total current assets

2,104

4,054

See original here:
AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update - Business Wire

Survivors of Pediatric Cancers May Experience Lasting Impact on Heart, Metabolic Health Following Radiation Therapy

Previous reports had been made regarding the impact of radiation therapy on the metabolic health of survivors of pediatric leukemia, brain tumors, and hematopoietic stem cell transplants. However, the radiation therapys effect on survivors of pediatric abdominal and pelvic tumors had not yet been assessed.

"Body composition abnormalities and cardiometabolic impairments are of concern among survivors given that in the general population, these conditions increase the risk of developing life-threatening diseases including cardiovascular disease and type 2 diabetes," said Carmen Wilson, PhD, assistant member in the Epidemiology and Cancer Control Department at St. Jude Children's Research Hospital, in a press release.

Specifically, the analyses showed that survivors of abdominal and pelvic solid tumors had low lean body mass, which is the measurement of the non-fat content of the body. The researchers found that survivors lean body mass was lower than the general population and that the lower relative lean body mass was connected with the prior abdominal or pelvic radiation. Those individuals with lower lean body mass burn fewer calories while resting than those with higher lean body mass, Wilson explained.

In conducting the study, the researchers assessed 431 adult survivors of pediatric abdominal or pelvic solid tumors who were treated at St. Jude Children's Research Hospital. At the time of the study, the median age of the participants was 29.9 years.

Of the childhood diagnoses, the most frequent were neuroblastoma, Wilms tumor, and germ cell tumor, with a median age of 3.6 years at diagnosis. Approximately 37% of participants had received abdominal radiation therapy and 36% had received pelvic radiation therapy during their treatment.

In order to assess the participants' body composition, metabolic abnormalities, and physical function in relation to the general population, the researchers used data from the 2013 to 2014 National Health and Nutrition Examination Survey (NHANES) that matched the age, sex, and ethnicity of the patients in the study.

The researchers found that compared with individuals from NHANES, the survivors of abdominal and pelvic solid tumors had a significantly higher likelihood of having insulin resistance (33.8% vs. 40.6%), high triglycerides (10.02% vs. 18.4%), and low levels of high-density lipoproteins (28.9% vs. 33.5%), which are commonly referred to as good cholesterol. However, the levels of low-density lipoproteins (bad cholesterol) between survivors and individuals from NHANES showed no significant differences.

"It is possible that abdominal and pelvic-directed radiation therapy damages postural muscles or subtly impairs sex hormone production, ultimately affecting muscle mass," Wilson said in the press release.

Radiation therapy has been previously shown to cause muscle injury, resulting in the loss of muscle fiber and muscle regenerative cells in animal studies, Wilson explained. She noted that lifestyle choices could potentially affect relative lean mass and cardiometabolic health as well.

The researchers said that it would be beneficial for future research on the topic to examine the effect of radiation therapy and other cancer treatments in relation to fat distribution in the body. This is of particular interest because increased abdominal obesity can be a stronger predictor of adverse effects than overall obesity, according to the study.

Additionally, Wilson noted that she is interested in investigating how lifestyle behaviors might influence lean mass among survivors of pediatric cancers.

"While it may not be possible to avoid radiation therapy as a key treatment for many solid tumors, early research suggests that resistance training interventions in survivors increase lean mass," Wilson said. "Further work is needed to see if training would also impact cardiometabolic impairments in this population."

REFERENCERadiation to treat pediatric cancers may have lasting impact on heart and metabolic health. American Association for Cancer Research; August 13, 2020. eurekalert.org/pub_releases/2020-08/aafc-rtt081020.php. Accessed August 14, 2020.

Read the original post:
Survivors of Pediatric Cancers May Experience Lasting Impact on Heart, Metabolic Health Following Radiation Therapy - Pharmacy Times

Global Stem Cell Reconstructive Marketwas valued US$ XX Mn in 2019 and is expected to reach US$ XX Mn by 2027, at a CAGR of 24.5% during a forecast period.

Market Dynamics

The Research Report gives an in-depth account of the drivers and restraints in the stem cell reconstructive market. Stem cell reconstructive surgery includes the treatment of injured or dented part of body. Stem cells are undifferentiated biological cells, which divide to produce more stem cells. Growing reconstructive surgeries led by the rising number of limbs elimination and implants and accidents are boosting the growth in the stem cell reconstructive market. Additionally, rising number of aged population, number of patients suffering from chronic diseases, and unceasing development in the technology, these are factors which promoting the growth of the stem cell reconstructive market. Stem cell reconstructive is a procedure containing the use of a patients own adipose tissue to rise the fat volume in the area of reconstruction and therefore helping 3Dimentional reconstruction in patients who have experienced a trauma or in a post-surgical event such as a mastectomy or lumpectomy, brain surgery, or reconstructive surgery as a result of an accident or injury. Stem cell reconstructive surgeries are also used in plastic or cosmetic surgeries as well. Stem cell and regenerative therapies gives many opportunities for development in the practice of medicine and the possibility of an array of novel treatment options for patients experiencing a variety of symptoms and conditions. Stem cell therapy, also recognised as regenerative medicine, promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

The common guarantee of all the undifferentiated embryonic stem cells (ESCs), foetal, amniotic, UCB, and adult stem cell types is their indefinite self-renewal capacity and high multilineage differentiation potential that confer them a primitive and dynamic role throughout the developmental process and the lifespan in adult mammal.However, the high expenditure of stem cell reconstructive surgeries and strict regulatory approvals are restraining the market growth.

The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Stem Cell Reconstructive Market Segment analysis

Based on Cell Type, the embryonic stem cells segment is expected to grow at a CAGR of XX% during the forecast period. Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their capability to distinguish into any embryonic cell type and by their ability to self-renew. Owing to their plasticity and potentially limitless capacity for self-renewal, embryonic stem cell therapies have been suggested for regenerative medicine and tissue replacement after injury or disease. Additionally, their potential in regenerative medicine, embryonic stem cells provide a possible another source of tissue/organs which serves as a possible solution to the donor shortage dilemma. Researchers have differentiated ESCs into dopamine-producing cells with the hope that these neurons could be used in the treatment of Parkinsons disease. Upsurge occurrence of cardiac and malignant diseases is promoting the segment growth. Rapid developments in this vertical contain protocols for directed differentiation, defined culture systems, demonstration of applications in drug screening, establishment of several disease models, and evaluation of therapeutic potential in treating incurable diseases.

Global Stem Cell Reconstructive Market Regional analysis

The North American region has dominated the market with US$ XX Mn. America accounts for the largest and fastest-growing market of stem cell reconstructive because of the huge patient population and well-built healthcare sector. Americas stem cell reconstructive market is segmented into two major regions such as North America and South America. More than 80% of the market is shared by North America due to the presence of the US and Canada.

Europe accounts for the second-largest market which is followed by the Asia Pacific. Germany and UK account for the major share in the European market due to government support for research and development, well-developed technology and high healthcare expenditure have fuelled the growth of the market. This growing occurrence of cancer and diabetes in America is the main boosting factor for the growth of this market.

The objective of the report is to present a comprehensive analysis of the Global Stem Cell Reconstructive Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Stem Cell Reconstructive Market dynamics, structure by analysing the market segments and projects the Global Stem Cell Reconstructive Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Stem Cell Reconstructive Market make the report investors guide.Scope of the Global Stem Cell Reconstructive Market

Global Stem Cell Reconstructive Market, By Sources

Allogeneic Autologouso Bone Marrowo Adipose Tissueo Blood Syngeneic OtherGlobal Stem Cell Reconstructive Market, By Cell Type

Embryonic Stem Cell Adult Stem CellGlobal Stem Cell Reconstructive Market, By Application

Cancer Diabetes Traumatic Skin Defect Severe Burn OtherGlobal Stem Cell Reconstructive Market, By End-User

Hospitals Research Institute OthersGlobal Stem Cell Reconstructive Market, By Regions

North America Europe Asia-Pacific South America Middle East and Africa (MEA)Key Players operating the Global Stem Cell Reconstructive Market

Osiris Therapeutics NuVasives Cytori Therapeutics Takeda (TiGenix) Cynata Celyad Medi-post Anterogen Molmed Baxter Eleveflow Mesoblast Ltd. Micronit Microfluidics TAKARA BIO INC. Tigenix Capricor Therapeutics Astellas Pharma US, Inc. Pfizer Inc. STEMCELL Technologies Inc.

Global Stem Cell Reconstructive Market Request For View Sample Report Page : @https://www.maximizemarketresearch.com/request-sample/54688

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:Name: Vikas GodageOrganization: MAXIMIZE MARKET RESEARCH PVT. LTD.Email: sales@maximizemarketresearch.comWebsite:www.maximizemarketresearch.com

Originally posted here:
Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Good Night, Good Hockey

Today (August 11), Big Idea Ventures (BIV) announces the launch of its second food technology accelerator program in New York City and Singapore. This years cohort includes 12 early-stage startups working in the plant-based and cell-based space, innovating new technologies that will be vital if we are to successfully shift towards a more sustainable food system. Below we highlight the exciting companies in BIVs latest cohort.

Founded: 2018

Founder: Vince Lu

Headquarters: Beijing, China

Mission: Zhenmeat is Chinas first and leading plant-based meat startup creating sustainable protein substitutes that are tailored to the Chinese palate. Its products include plant-based pork, mooncakes, sausages and meatballs, made from pea protein, fungus, cellulose, coconut oil and various natural flavour extracts and spices. Zhenmeat is also working on vegan crayfish and pork tenderloin. Their products are currently sold online and through various restaurant partners in China.

Founded: 2019

Founders: Stephen Michael Co, Carlo Antonio Ng & Carissa Jane Lim

Headquarters: Manila, Philippines

Mission: WTH Foods (Worth The Health) is a plant-based meat company developing sustainable alternatives made using carefully-sourced local ingredients and inspired by regional flavours. Its products include pinoy pulled jackfruit pork, jackfruit nuggets and mung bean-based ground meat. WTH Foods products are currently available online via its website.

Founded: 2019

Founder: Vinayaka Srinivas & Thanh Hung Nguyen

Headquarters: Singapore

Mission: GaiaFoods is Singapores first cell-based red meat company. Using stem cell biotechnology, the company cultivates meat that tastes and looks exactly like real meat but without the need to harm animals, making it a cruelty-free and sustainable alternative, and does not contain any hormones, antibiotics or the use of any toxic chemicals.

Founded: 2015

Founders: Alejandro Cancino & Paola Moro

Headquarters: Brisbane, Australia

Mission: Fenn Foods is an Australian startup creating healthy, affordable and tasty plant-based protein alternatives made using ethically sourced ingredients such as textured vegetable protein derived from soybeans, yeast extract and pea protein. Its products include a beef alternative dubbed veef, schnitzel and chicken burger patties. The company does not use any ingredients that are GMO and source as many local and organic produce as possible.

Founded: 2020

Founder: Nieves Martnez Marshall

Headquarters: Berkeley, California, U.S.

Mission: Novel Farms, Inc. uses synthetic biology to make cruelty-free, cost-efficient and functionalised 3D scaffolds for the production of structured cultured meats and their first project is jamon iberico. Its technology helps to improve the marbling and texture of cell-based meats and can also reduce manufacturing costs. Its mission is to transform more sustainable and slaughter-free cell-based meats into a sought-after culinary experience.

Founded: 2013

Founder: Aleem Ahmed

Headquarters: San Francisco, California, U.S.

Mission: Wild For Co. connects farmers to families by creating nutritious and delicious foods using the ancient Ethiopian superfood grain teff. Its star product is a vegan-friendly air-popped chip made with teff, which is naturally gluten-free, high-protein, high-fibre and is packed with nutrients such as calcium, iron and the essential amino acids.

Founded: 2019

Founders: Kartik Dixit & Shraddha Bhansali

Headquarters: Mumbai, India

Mission: EVO Foods is Indias first plant-based egg startup using food science and plant biochemistry to develop a vegan egg alternative. Its first product is a 100% plant-based liquid egg made from protein derived from lentils, which contains no cholesterol and antibiotics. It recently received angel investment from Wild Earth founder Ryan Bethencourt, as well as VegInvest and Shiok Meats co-founder Sandhya Sriram.

Founded: 2019

Founder: Patricia Bubner

Headquarters: Berkeley, California, U.S.

Mission: Orbillion Bio is a startup looking to develop premium cell-based meat products from heritage cell lines that are directly sourced from farmers. On a mission to accelerate the broad availability of a variety of nutritious cultivated meat products, the startups first product will be bison jerky that is low-fat, low-cholesterol and high-protein.

Founded: 2020

Founders: Darko Mandich & Aaron Schaller

Headquarters: Berkeley, California, U.S.

Mission: MeliBio is using microbiology to cultivate sustainable and clean honey that has the same taste and nutritional profile as conventional honey. Because it is produced without traditional beekeeping techniques, its honey does not harm pollinator diversity, especially wild and native bee populations, which have been jeopardized over the years by the expansion of commercial beekeeping.

Founded: 2020

Founders: Jason Rosenbaum & Hailey Swartz

Headquarters: New York City, New York, U.S.

Mission: Actual Veggies creates chef-crafted fresh and refrigerated burgers that puts vegetables front and centre all their burgers are colourful, showcasing their primary vegetable ingredient. They contain only fresh farm veggies and natural binding units, such as kale, sweet potatoes, mushrooms and beets. With added plant proteins such as legumes and seeds, each patty has around 10 grams of protein.

Founded: 2018

Founders: Kerem Erikci & Can Akcali

Headquarters: Ankara, Turkey

Mission: Biftek.co is a startup producing cultivated medium that can replace fetal-bovine-serum (FBS) in the production of cell-based meats. Using its novel culture supplement formulation to grow muscle stem cells, its solution is 80% to 90% less expensive, which can help food techs lower the cost of producing cultivated proteins.

Founded: 2016

Founder: Bonnie Lau

Headquarters: San Francisco, California, U.S.

Mission: Yoconut is a plant-based dairy brand creating delicious, healthy and allergy-friendly coconut-based yoghurts that contain live cultures and no added sugar. Currently, the brand has five vegan coconut yoghurt products in various flavours, and is available online as well as in a number of stores across California.

Lead image courtesy of Veef / Fenn Foods.

Here is the original post:
Meet The 12 Next-Gen Food Techs Transforming The Future Of Protein - Green Queen Media

Honeywell is getting the collaborative spirit:Honeywell, which recently signed a partnership with SAP to help organizations understand the financial performance of their buildings, has signed onto another collaboration, this time with oil services giant Halliburton. The focus here is on both collaboration and bringing data from each companys software to build new products and services. This is where the internet of things can really start to create value, because no one company will have all of the data necessary to document a business process. Its worth paying attention to these deals, noting how well they actually progress and what customers adopt. That way we can track if customers are really buying into the promise of IoT and, in turn, delivering value as part of an ecosystem. (Seeking Alpha)

Were finallyready to talk about standards for consumer wearables for medical-grade use cases: Silicon Valley has rushed to deliver wellness products in the form of activity trackers, sleep trackers, connected blood pressure cuffs, and EKG devices that run on your smartphone. But for the most part, these arent sufficient for medical-grade use cases because the data they produce isnt standardized or consistently tested in peer-reviewed studies. With the rush toward the remote monitoring of patients and remotely conducted clinical trials, the medical device industry is calling for Silicon Valley to help corral the Wild West of Datathat has emerged. In this essay, the authors call for companies to sign on to use standard, clinically validated methodologies for data collecting and sharing so researchers can compare results from patients wearing Fitbits to those wearing Apple Watches. Because while its fine if proprietary algorithms are used for the consumer-facing apps, for clinical trials, there needs to be more transparency. (Stat)

COVID cuts smart home revenue estimates:ABI Research says that in 2020, smart home device spending will rise by 4% from the prior year, to $85 billion. However, the new figure represents a $14.1 billiondecline in predicted sales, since prior to the pandemic analysts expected spending to rise by 21%.This data actually surprised me because it suggests that COVID-19 has cut the adoption of smart home devices despite many of us spending far more time at home. Given that job losses and economic uncertainty make it hard to shell out $50 for a smart light bulb, and that expensive security cameras arent really necessary if you never leave home, I guess the data makes sense. But I also wonder how many people are, like me, tired of reading about privacy violations and devices that lose their functionality and/or have security flaws. (CE Pro)

Its a cardiologist in a box?A startup called Bodyport has raised $11.2 million for its connected scale, which is designed to measure health. The scale is part of an overall medical-grade service that links a patient to their cardiologist and helps both track heart data without the need for in-person visits to a clinic. Im assuming that because of the pandemic the company sees a chance to push its version of sensors and algorithms to the medical industry and the masses. But at this point Im a little burned out by the mess of products competing to provide health monitoring without a focus on creating data standards and new systems for helping doctors manage what will be a huge influx of data.(Bodyport)

This is a fun-sounding startup: Las Vegas-based Terbine is trying to create a real-world market for data. This is a concept Ive been excited about for more than a decade, but technical and logistical challenges seem to keep it forever on the sidelines. On the technical side, some of the challenges include trying to move large amounts of data and the speed at which some data becomes stale. For example, weather data may be relevant for a long time, but theres a lot of it, so transferring it to another party comes with storage and associated bandwidth costs (the data gravity problem). Also, certain data such as traffic light data is only good for a few seconds or minutes, so a market would have to be faster than current ad exchanges. On the logistical side, most companies believe that their data is the new oil and want to hoard it, despite not knowing what to do with it or realizing that it would be more valuable when combined with data from other firms. So Ill keep an eye on Terbine because, as I said, I love this idea. (IMC)

Apptricity releases a Bluetooth tracker that can go the distance: Apptricity has shown off a Bluetooth hub and tracker that can measure a location for 20 miles, far beyond the typical 30-to-100-foot range that Bluetooth radio waves can travel. The boost means that Apptricity Bluetooth devices can compete with SigFox, LoRa, and other Low-Power Wide-Area Networks for tracking devices across large corporate campuses and warehouse settings. (Apptricity)

Personalized medicine could be coming closer:One of the ideas celebrated by futurists is that AI and the IoT can help deliver medical interventions personalized for each individual. This requires pretty intrusive surveillance of your body, but if you could get a customized treatment for your cancer that killed the cancerous cells while minimizing any side effects, youd probably take it. Now UCLA Samueli School of Engineering and the Stanford School of Medicine have built a smartwatch that analyzes a persons sweat to detect trace amounts of medicine in their body. This would allow doctors to calculate the exact amount of a drug that would be effective for each patient possibly reducing both the side effects and cost of treatment. (Medgadget)

This is a deep dive into new ways of performing machine learning on time-series data: For those of yall who are familiar with convolutional neural networks, recurrent neural networksand other ways of training computers to extract meaning from data, this article talks about a new technique that combines different training models and is optimized for time-series data. They are called temporal convolutional networks or TCNs. This is relevant for IoT folks, because a lot of the data generated by sensors is time-series data, and more efficient ways to train algorithms to handle such data could benefit many IoT applications. This is a dense read, but worth it. (Medium)

SiFive just got a lot more money: SiFive, the company making it easier for designers to build RISC-V processors, has raised $61 million in Series E funding, bringing its total funding to about $190 million. The company is banking on a new open-source chip architecture calledRISC-V that competes with MIPS, x86, and the Arm architecture. RISC-V is gaining ground because it doesnt have the high licensing fees associated with some of the other options, and because designers can freely customize it for specific workloads. A few companies are using RISC-V chips to build chips for the IoT.(HPC Wire)

Related

Original post:
IoT news of the week for August 14, 2020 - Stacey on IoT

BOZEMAN, Mont., Aug. 12, 2020 /PRNewswire/ --Golden Helix has secured its reputation as a global leader in Next-Generation Sequencing solutions for over two decades. Today, they have been included in the esteemed Inc. 5000 list of rapidly growing American companies. Out of the 6 million business in the United States, Golden Helix has been honored with a spot in the annual list for the 2nd consecutive year.

Being ranked in the top 5000 places, Golden Helix is among some of the fastest growing and highly respected companies in both size and revenue a testament to the company's focus on innovation, quality, and customer satisfaction.

"We are ecstatic to be named among the country's leading companies. Next-Generation Sequencing is here to stay, and we are very appreciative to be experiencing global adoption of our solution stack," said Dr. Andreas Scherer, President and CEO of Golden Helix. "Our industry-leading CNV analytics capabilities in conjunction with state-of-the-art clinical workflows to diagnose cancer and rare diseases have differentiated ourselves in the marketplace. On top of that, we provide secure and scalable enterprise deployment capabilities with our data warehouse solution."

Of the tens of thousands of companies that have applied over the years, only a fraction of them makes the list more than once. The recognition comes on the heels of Golden Helix also being recognized by Healthcare Tech Outlook on its list of Top 10 Genetic Diagnostics Companies of 2020.

"The whole team at Golden Helix would like to thank each of our customers and partners for helping us become one of the fastest-growing biotech firms in the country," said Dr. Scherer. "I also want to thank the entire team at Golden Helix for all the creativity and dedication over many years in a competitive marketplace. We're honored to receive this recognition among so many remarkable companies."

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.

Delaina HawkinsGolden Helix, Inc(406) 999-0176[emailprotected]

SOURCE Golden Helix Inc

http://www.goldenhelix.com

More here:
Golden Helix, Inc. Claims Position on Acclaimed Inc. 5000 List of Fastest-Growing Private Companies for Second Year Running - PRNewswire

LLS announced today, Rich Pentz and Tina Swallow were awarded the prestigious titles, National Man of the Year and National Woman of the Year, and broke new local campaign records, raising $518,906 and $467,686 respectively. The campaign has helped LLS invest nearly$1.3 billion, ensuring that the organization continues to deliver its cancer curing mission and impact for patients, who need support now, more than ever.

The funds raised through Man & Woman of the Year are used for:

"Cancer will not wait for COVID-19 to go away. And cancer patients can't wait either," said Louis J. DeGennaro, Ph.D., LLS president and CEO. "With the grit and determination of LLS supporters and volunteers like our Man & Woman of the Year candidates, LLS maintains a very significant, impactful mission agenda. We will continue to forge ahead relentlessly to find cures and help blood cancer patients access the care they need."

Pentz, a senior director of institutional sales and relationship management at Principal Global Investors in Indianapolis, IN, spearheaded "Team Echo" after accepting his nomination in memory of his mother, Patricia, who lost her battle to acute myeloid leukemia six years ago. He leveraged social media and organizedinnovative fundraising tactics in lieu of his other event plans, which were canceled due to COVID-19. Pentz said he was "elated beyond words" to find out his campaign, which culminated on his mother's birthday, June 20, broke a new fundraising record for Indiana."It's not about winning the title, it's about the impact we're makingon the cancer landscape," said Pentz.

Swallow, a 21-year Navy veteran and services director at Cisco in Washington, D.C., led "Team Bridge to a Cure" and ran her campaign in honor of her oldest son, Beau, who survived stage 4 cancer. "I've made it my mission to never stop fighting for cancer cures," said Swallow. "Just like LLS, my mission has not changed, what has changed is the urgency for patients."

The National Man & Woman of the Year runners-up were Jesse Giordano of "Team Unity" of Opal Wealth Advisors in Long Island, NY, and Lauren Palmer of "Team Gold" in Charlotte, NC they raised $437,510 and $352,792, respectively. The National "All Star" winners were Brian Fuller of "Team Lexie's Legacy" in Atlanta, GA, and Allison Jockel of "Team AML All Stars" in Charlotte, NC. Collectively, they raised more than $542,192. Fuller broke a new national All Star fundraising record and ran his campaign in memory of Lexie Clayton, a former LLS staff member who passed away from cancer at 36 years old.

To learn more about Man & Woman of the Year, visitwww.mwoy.org.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society (LLS) is a global leader in the fight against cancer. The LLS mission: cure leukemia, lymphoma, multiplemyeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.

Founded in 1949 and headquartered in Rye Brook, NY, LLS has chapters throughout the United States and Canada. To learn more, visit http://www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m., ET.

For additional information visitlls.org/lls-newsnetwork. Follow us onFacebook,Twitter, andInstagram.

The LLS Children's Initiative: Cures and Care for Children with Cancer

TheLLS Children's Initiativeis a $100 million multi-year effort to take on children's cancer through every facet of LLS's mission: research, patient education and support and policy and advocacy. The LLS Children's Initiative includes: more pediatric research grants, a global precision medicine clinical trial, expanded free education and support services for children and families and driving policies and laws that break down barriers to care. To learn more, visitwww.lls.org/childrens-initiative.

Media Contact:Kristin Hoose[emailprotected](914) 821-8973

SOURCE The Leukemia & Lymphoma Society (LLS)

http://www.lls.org

See the original post here:
Communities Nationwide Remain Laser-Focused on Helping Cancer Patients Who Can't Wait For Pandemic to Go Away - PRNewswire

New Jersey, United States,- Verified Market Researchhas recently published an extensive report on the Personalized Medicine Market to its ever-expanding research database. The report provides an in-depth analysis of the market size, growth, and share of the Personalized Medicine Market and the leading companies associated with it. The report also discusses technologies, product developments, key trends, market drivers and restraints, challenges, and opportunities. It provides an accurate forecast until 2027. The research report is examined and validated by industry professionals and experts.

The report also explores the impact of the COVID-19 pandemic on the segments of the Personalized Medicine market and its global scenario. The report analyzes the changing dynamics of the market owing to the pandemic and subsequent regulatory policies and social restrictions. The report also analyses the present and future impact of the pandemic and provides an insight into the post-COVID-19 scenario of the market.

Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of10.67% from 2019-2026 and reachUSD 217.90 Billion by 2026.

The report further studies potential alliances such as mergers, acquisitions, joint ventures, product launches, collaborations, and partnerships of the key players and new entrants. The report also studies any development in products, R&D advancements, manufacturing updates, and product research undertaken by the companies.

Leading Key players of Personalized Medicine Market are:

Competitive Landscape of the Personalized Medicine Market:

The market for the Personalized Medicine industry is extremely competitive, with several major players and small scale industries. Adoption of advanced technology and development in production are expected to play a vital role in the growth of the industry. The report also covers their mergers and acquisitions, collaborations, joint ventures, partnerships, product launches, and agreements undertaken in order to gain a substantial market size and a global position.

Regional Analysis of Personalized Medicine Market:

A brief overview of the regional landscape:

From a geographical perspective, the Personalized Medicine Market is partitioned into

North Americao U.S.o Canadao MexicoEuropeo Germanyo UKo Franceo Rest of EuropeAsia Pacifico Chinao Japano Indiao Rest of Asia PacificRest of the World

Key coverage of the report:

Other important inclusions in Personalized Medicine Market:

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Continue reading here:
Personalized Medicine Market Size by Top Companies, Regions, Types and Application, End Users and Forecast to 2027 - Bulletin Line

Overview of Cancer/ Tumor Profiling Market Report Helps In Providing Scope and Definitions, Key Findings, Growth Drivers, and Various Dynamics.

The global Cancer/ Tumor Profiling market focuses on encompassing major statistical evidence for the Cancer/ Tumor Profiling industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Cancer/ Tumor Profiling study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked.

This intelligence and 2026 forecasts Cancer/ Tumor Profiling industry report further exhibits a pattern of analyzing previous data sources gathered from reliable sources and sets a precedented growth trajectory for the Cancer/ Tumor Profiling market. The report also focuses on a comprehensive market revenue streams along with growth patterns, analytics focused on market trends, and the overall volume of the market.

Moreover, the Cancer/ Tumor Profiling report describes the market division based on various parameters and attributes that are based on geographical distribution, product types, applications, etc. The market segmentation clarifies further regional distribution for the Cancer/ Tumor Profiling market, business trends, potential revenue sources, and upcoming market opportunities.

Download PDF Sample of Cancer/ Tumor Profiling Market report @ https://hongchunresearch.com/request-a-sample/58977

Key players in the global Cancer/Tumor Profiling market covered in Chapter 4:Illumina Inc. (U.S.)HTG Molecular Diagnostic (U.S.)Genomic Health Inc. (U.S.)NeoGenomics Laboratories (U.S.)QIAGEN N.V. (Netherlands)

In Chapter 11 and 13.3, on the basis of types, the Cancer/Tumor Profiling market from 2015 to 2026 is primarily split into:Next-generation SequencingIn Situ HybridizationImmunohistochemistryQuantitative PCR

In Chapter 12 and 13.4, on the basis of applications, the Cancer/Tumor Profiling market from 2015 to 2026 covers:Personalized MedicineBiomarker DiscoveryDiagnosticsPrognostics

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:North America (Covered in Chapter 6 and 13)United StatesCanadaMexicoEurope (Covered in Chapter 7 and 13)GermanyUKFranceItalySpainRussiaOthersAsia-Pacific (Covered in Chapter 8 and 13)ChinaJapanSouth KoreaAustraliaIndiaSoutheast AsiaOthersMiddle East and Africa (Covered in Chapter 9 and 13)Saudi ArabiaUAEEgyptNigeriaSouth AfricaOthersSouth America (Covered in Chapter 10 and 13)BrazilArgentinaColumbiaChileOthers

The Cancer/ Tumor Profiling market study further highlights the segmentation of the Cancer/ Tumor Profiling industry on a global distribution. The report focuses on regions of North America, Europe, Asia, and the Rest of the World in terms of developing business trends, preferred market channels, investment feasibility, long term investments, and environmental analysis. The Cancer/ Tumor Profiling report also calls attention to investigate product capacity, product price, profit streams, supply to demand ratio, production and market growth rate, and a projected growth forecast.

In addition, the Cancer/ Tumor Profiling market study also covers several factors such as market status, key market trends, growth forecast, and growth opportunities. Furthermore, we analyze the challenges faced by the Cancer/ Tumor Profiling market in terms of global and regional basis. The study also encompasses a number of opportunities and emerging trends which are considered by considering their impact on the global scale in acquiring a majority of the market share.

The study encompasses a variety of analytical resources such as SWOT analysis and Porters Five Forces analysis coupled with primary and secondary research methodologies. It covers all the bases surrounding the Cancer/ Tumor Profiling industry as it explores the competitive nature of the market complete with a regional analysis.

Brief about Cancer/ Tumor Profiling Market Report with [emailprotected] https://hongchunresearch.com/report/cancer-tumor-profiling-market-2020-58977

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Cancer/Tumor Profiling Market

Chapter Four: Players Profiles

Chapter Five: Global Cancer/Tumor Profiling Market Analysis by Regions

Chapter Six: North America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Seven: Europe Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eight: Asia-Pacific Cancer/Tumor Profiling Market Analysis by Countries

Chapter Nine: Middle East and Africa Cancer/Tumor Profiling Market Analysis by Countries

Chapter Ten: South America Cancer/Tumor Profiling Market Analysis by Countries

Chapter Eleven: Global Cancer/Tumor Profiling Market Segment by Types

Chapter Twelve: Global Cancer/Tumor Profiling Market Segment by Applications12.1 Global Cancer/Tumor Profiling Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Cancer/Tumor Profiling Sales and Market Share by Applications (2015-2020)12.1.2 Global Cancer/Tumor Profiling Revenue and Market Share by Applications (2015-2020)12.2 Personalized Medicine Sales, Revenue and Growth Rate (2015-2020)12.3 Biomarker Discovery Sales, Revenue and Growth Rate (2015-2020)12.4 Diagnostics Sales, Revenue and Growth Rate (2015-2020)12.5 Prognostics Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Cancer/Tumor Profiling Market Forecast by Regions (2020-2026) continued

Check [emailprotected] https://hongchunresearch.com/check-discount/58977

List of tablesList of Tables and FiguresTable Global Cancer/Tumor Profiling Market Size Growth Rate by Type (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Type in 2019 & 2026Figure Next-generation Sequencing FeaturesFigure In Situ Hybridization FeaturesFigure Immunohistochemistry FeaturesFigure Quantitative PCR FeaturesTable Global Cancer/Tumor Profiling Market Size Growth by Application (2020-2026)Figure Global Cancer/Tumor Profiling Market Share by Application in 2019 & 2026Figure Personalized Medicine DescriptionFigure Biomarker Discovery DescriptionFigure Diagnostics DescriptionFigure Prognostics DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Cancer/Tumor Profiling Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Cancer/Tumor Profiling Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Cancer/Tumor ProfilingFigure Production Process of Cancer/Tumor ProfilingFigure Manufacturing Cost Structure of Cancer/Tumor ProfilingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Illumina Inc. (U.S.) ProfileTable Illumina Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table HTG Molecular Diagnostic (U.S.) ProfileTable HTG Molecular Diagnostic (U.S.) Production, Value, Price, Gross Margin 2015-2020Table Genomic Health Inc. (U.S.) ProfileTable Genomic Health Inc. (U.S.) Production, Value, Price, Gross Margin 2015-2020Table NeoGenomics Laboratories (U.S.) ProfileTable NeoGenomics Laboratories (U.S.) Production, Value, Price, Gross Margin 2015-2020Table QIAGEN N.V. (Netherlands) ProfileTable QIAGEN N.V. (Netherlands) Production, Value, Price, Gross Margin 2015-2020Figure Global Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Global Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Global Cancer/Tumor Profiling Sales by Regions (2015-2020)Table Global Cancer/Tumor Profiling Sales Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue ($) by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions (2015-2020)Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2015Table Global Cancer/Tumor Profiling Revenue Market Share by Regions in 2019Figure North America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Europe Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South America Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure North America Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table North America Cancer/Tumor Profiling Sales by Countries (2015-2020)Table North America Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table North America Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table North America Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure North America Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure United States Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Canada Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Mexico Cancer/Tumor Profiling Sales and Growth (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue ($) Growth (2015-2020)Table Europe Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Europe Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Europe Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Europe Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure Germany Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure UK Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure France Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Italy Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Spain Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Russia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Sales Market Share by Countries in 2019Table Asia-Pacific Cancer/Tumor Profiling Revenue ($) by Countries (2015-2020)Table Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2015Figure Asia-Pacific Cancer/Tumor Profiling Revenue Market Share by Countries in 2019Figure China Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Japan Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure South Korea Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Australia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure India Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Southeast Asia Cancer/Tumor Profiling Sales and Growth Rate (2015-2020)Figure Middle East and Africa Cancer/Tumor Profiling Revenue ($) and Growth (2015-2020) continued

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Read more here:
Impact Of Covid-19 on Cancer/ Tumor Profiling Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

DUBLIN--(BUSINESS WIRE)--The "Global DNA Sequencing Market: Growth, Trends & Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The Global DNA Sequencing Market is expected to witness a CAGR of 18.9% during the forecast period.

Certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis & drug discovery, and growing investment in R&D.

The technological advancements in sequencing, from 2D sequencing in the 1970's to DNA sequencing, has come a long way. In the recent years, platforms, such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos, have provided unique prospects for high-throughput functional genomic research. After the introduction of NGS technologies in 2005, they have had an incredible influence on genomic research.

Next-generation sequencing, currently, has its application in the diagnosis of a variety of illnesses, such as cancer, hematological disorders, neurology, psychiatry, dysmorphology, vision and hearing impairment, cardiology, and pharmacogenomics. It is also used as a tool for noninvasive prenatal tests. NGS technologies have been used for standard sequencing applications, like genome sequencing and for novel applications that were previously unexplored by using Sanger sequencing.

Applications include whole genome and transcriptome sequencing, metagenomic characterization of microbial types in environmental and clinical specimens, explanation of DNA binding sites for chromatin and regulatory proteins, and targeted re-sequencing of specific sites in the human genome, identified by linkage analyses.

Key Market Trends

Next Generation Sequencing is Expected to Show Lucrative Growth Opportunity in the Platform Segment

Next Generation Sequencing can be of several types based on the technology. For example, the benefits offered by whole genome sequencing technique, such as ease of handling, affordability, and accuracy, are expected to boost their demand. Additionally, these tests are usually preferred by the market players as a single test, which is capable of providing information on multiple factors, such as virulence, serotype, and resistance.

FDA is applying NGS in innovative ways, which can help reduce foodborne illnesses and deaths. Isolation of pathogens from food or environmental samples may be compared to clinical isolates from patients. A reliable link between the two is made, which helps define the scope of a foodborne illness outbreak. Owing to such factors the concerned segment is expected to observe a steady growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

The North America dominated the global market studied, in 2018, owing to the increasing funding and support activities by the government and non-government entities, especially in the United States. By supporting genomics research, various government bodies, like NHGRI (National Human Genome Research Institute) have supported the work on sequencing of the human genome, and fund research on the genome's structure, function, and role in health and disease.

They also support studies on the ethical, legal, and social implications (ELSI) of genome research. The US National Human Genome Research Institute and the US National Academy of Medicine, organized 90 leaders in genomic medicine from the United States, and 25 other countries in Genomic Medicine Symposium in 2014, in order to identify opportunities for collaborations that promote the responsible practice of genomic medicine.

Competitive Landscape

The DNA Sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina, Inc., Merck KGaA, Pacific Biosciences of California, Inc., PerkinElmer Inc., Thermo Fisher Scientific, Inc., among others, hold the substantial market share in the DNA Sequencing market.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Rise in Technological Advancements in DNA Sequencing

4.2.2 Increasing Application in Clinical Diagnosis & Drug Discovery

4.2.3 Growing Investment in R&D

4.3 Market Restraints

4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals

4.3.2 Legal and Ethical Issues

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 Product Type

5.1.1 Instruments

5.1.2 Consumables (Kits, Reagents)

5.1.3 Others

5.2 Platform

5.2.1 Sanger

5.2.2 Next Generation Sequencing

5.2.3 qPCR

5.2.4 Others

5.3 Application

5.3.1 Diagnostics

5.3.2 Personalized Medicine

5.3.3 Others (Biomarkers, Forensics, Reproductive Health etc.)

5.4 End User

5.4.1 Hospitals and Healthcare Organizations

5.4.2 Academics and Research Institutions

5.4.3 Pharmaceutical and Biotechnology Companies

5.4.4 Others

5.5 Geography

5.5.1 North America

5.5.2 Europe

5.5.3 Asia Pacific

5.5.4 Middle East and Africa

5.5.5 South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies, Inc.

6.1.2 Bio-Rad Laboratories, Inc.

6.1.3 Danaher Corporation (Beckman Coulter, Inc.)

6.1.4 Eurofins Scientific

6.1.5 F. Hoffmann-La Roche

6.1.6 Illumina, Inc.

6.1.7 Merck KGaA

6.1.8 Pacific Biosciences of California, Inc.

6.1.9 PerkinElmer Inc.

6.1.10 Thermo Fisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/29pmu9

Read this article:
DNA Sequencing Industry Outlook 2020-2025 - Increasing Application in Clinical Diagnosis & Drug Discovery is Driving Growth -...

Written by AZoRoboticsAug 14 2020

Researchers from the Eye Clinic of the University Hospital Bonn, Stanford University, and the University of Utah have developed an artificial intelligence (AI)-based software that enables the accurate evaluation of the progression of geographic atrophy (GA).

Geographic atrophy is a disease of the light-sensitive retina that occurs due to age-related macular degeneration (AMD).

This novel technique enables fully automated measurement of the main atrophic lesions with the help of data obtained from optical coherence tomography, which offers three-dimensional visualization of the retinas structure.

Moreover, the researchers can accurately identify the integrity of light-sensitive cells of the whole central retina, as well as detect progressive degenerative variations of what are called the photoreceptors beyond the main lesions.

The study results will be used to evaluate the effectiveness of new innovative therapeutic approaches. The study was published recently in the JAMA Ophthalmology journal.

Currently, there exists no viable treatment for geographic atrophy, which is one of the most common reasons for blindness in industrialized nations. The disease impairs the cells of the retina and destroys them.

The main lesions, regions of the degenerated retina, also called geographic atrophy, tend to expand with the progression of the disease and lead to blind spots in the visual field of the patient. A main difficulty faced in the case of assessment therapies is that the lesions tend to progress gradually, implying that a long follow-up period is required for intervention studies.

When evaluating therapeutic approaches, we have so far concentrated primarily on the main lesions of the disease. However, in addition to central visual field loss, patients also suffer from symptoms such as a reduced light sensitivity in the surrounding retina.

Dr Frank G. Holz, Professor and Director, Eye Clinic, University Hospital Bonn.

Dr Holz added, Preserving the microstructure of the retina outside the main lesions would therefore already be an important achievement, which could be used to verify the effectiveness of future therapeutic approaches.

Moreover, the researchers could demonstrate that the integrity of light-sensitive cells exterior to the geographic atrophy areas is a predictor of the future progression of the disease.

It may therefore be possible to slow down the progression of the main atrophic lesions by using therapeutic approaches that protect the surrounding light sensitive cells.

Monika Fleckenstein, Professor, Moran Eye Center, University of Utah

Prof. Fleckenstein is the initiator of the Bonn-based natural history study on geographic atrophy, based on which this study was performed.

Research in ophthalmology is increasingly data-driven. The fully automated, precise analysis of the finest, microstructural changes in optical coherence tomography data using AI represents an important step towards personalized medicine for patients with age-related macular degeneration.

Dr Maximilian Pfau, Study Lead Author, Eye Clinic, University Hospital Bonn

Dr Pfau, who is currently a fellow of the German Research Foundation (DFG) and postdoctoral fellow at Stanford University in the Department of Biomedical Data Science, added that It would also be useful to re-evaluate older treatment studies with the new methods in order to assess possible effects on photoreceptor integrity.

Pfau, M., et al. (2020) Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration. JAMA Ophthalmology. doi.org/10.1001/jamaophthalmol.2020.2914.

Source: https://www.uni-bonn.de/en?set_language=en

Continue reading here:
New AI-Based Software Precisely Assesses Progression of Retinal Legions from Geographic Atrophy - AZoRobotics

The "Healthcare Descriptive Analysis Market: Growth, Trends and Forecasts (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Increasing need to reduce healthcare expenditure, including cost associated with medical product flaws and hospital workflow inefficiencies, is anticipated to increase the usage of big data in the healthcare sector.

The digitalization of healthcare data is also one of the primary drivers of healthcare analytics. According to Intel, approximately more than 80% of the healthcare organizations in the U.S. have adopted Electronic Medical Records (EMR) systems. These systems collect a lot of data, which can be analyzed using various types of healthcare analytics to develop personalized medicine.

Advanced methods such as predictive analytics are widely used in government organizations such as healthcare financing systems primarily to avoid frauds in payments. For instance, in 2011, the Centers of Medicare and Medicaid Services (CMS) reported that under its Fraud Prevention System (FPS), predictive analytics helped in saving USD 1.5 billion through improper payments. Moreover, the CMS is developing next generation predictive analytics, which is expected to boost the usage of predictive analytics.

Key Market Trends

Financial Data Analytics Segment Expected to Dominate the Market Over the Forecast Years

By application, the market has been segmented into clinical, financial, administrative, and research data analytics. The Financial Data Analytics segment is expected to register significant growth during the forecast period due to the technologically advanced solutions by healthcare providers and increased focus of payers on the early detection of fraud and reducing preventable costs.

North America Expected to Dominate the World Market

North America is expected to dominate the market followed by Europe. Factors, such as growing federal healthcare mandates to curb rising healthcare costs and provide quality care; increasing regulatory requirements; growing EHR adoption; and rising government initiatives focusing on personalized medicine, population health management, and value-based reimbursements are expected to drive market growth in North America.

Competitive Landscape

The Healthcare Descriptive Analysis market is moderately competitive and many of the global players are into the market. For instance - IBM, Inovalon, Cerner Corporation, Oracle Corporation, McKesson Corporation, MedeAnalytics, Inc., Optum, Inc., Allscripts Healthcare Solutions, Inc., etc. are providing healthcare descriptive analysis products across the globe.

Key Topics Covered

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Need for Comprehensive Analytics

4.2.2 Integration of Big Data into Healthcare

4.3 Market Restraints

4.3.1 Data Privacy and Security Concerns

4.3.2 High Costs of Initial Investment

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Clinical Data Analytics

5.1.2 Financial Data Analytics

5.1.3 Administrative Data Analytics

5.1.4 Research Data Analytics

5.2 By Component

5.2.1 Software

5.2.2 Hardware

5.2.3 Services

5.3 By Deployment

5.3.1 On-Premise

5.3.2 Web-based

5.3.3 Cloud based

5.4 By End-user

5.4.1 Private organization

5.4.1.1 Hospitals

5.4.1.2 Physicians

5.4.1.3 Clinics

5.4.1.4 Others

5.5 Geography

5.5.1 North America

5.5.1.1 United States

5.5.1.2 Canada

5.5.1.3 Mexico

5.5.2 Europe

5.5.2.1 Germany

5.5.2.2 UK

5.5.2.3 France

5.5.2.4 Italy

5.5.2.5 Spain

5.5.2.6 Rest of Europe

5.5.3 Asia-Pacific

5.5.3.1 China

5.5.3.2 Japan

5.5.3.3 India

5.5.3.4 Australia

5.5.3.5 South Korea

5.5.3.6 Rest of Asia-Pacific

5.5.4 Middle-East and Africa

5.5.4.1 GCC

5.5.4.2 South Africa

5.5.4.3 Rest of Middle-East and Africa

5.5.5 South America

5.5.5.1 Brazil

5.5.5.2 Argentina

5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 IBM

6.1.2 Allscripts Healthcare Solutions, Inc.

6.1.3 Cerner Corporation

6.1.4 Inovalon

6.1.5 McKesson Corporation

6.1.6 MedeAnalytics, Inc.

6.1.7 Optum

6.1.8 Oracle Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/iflgkx

View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005670/en/

Go here to see the original:
Healthcare Descriptive Analysis Industry 2020-2025: Financial Data Analytics Expected to Dominate Over the Forecast Period - ResearchAndMarkets.com -...

The Biomarkers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Our analysts monitoring the situation around the Globe explain that after COVID-19 crisis the market will generate remunerative prospects for producers. The goal of the report is to provide a further illustration of the current scenario, economic slowdown and effect of COVID-19 on the industry as a whole.

Biomarkers Market was valued at USD 36.3 Billion in 2018 and expected to reach USD 91.4 Billion by 2025 with a CAGR of 14.1% during the forecast period. Increasing prevalence of cancer and growing precision medicine market are amongst the pivotal factors anticipated to spur the growth of Biomarkers Market.

The global biomarkers market is witnessing a healthy growth trajectory attributed to the growing application of biomarkers in diagnostics, increasing funding for biomarkers research, as well as its rising usage in drug discovery. Biomarkers are biological molecules found in body fluids and tissues that help in crucial clinical decision making and diagnosing various health conditions of the patients. Since the molecules can analyze pharmacological responses and pathological indications, they can effectively assist in process of drug discovery and development.

The diagnostics industry has been witnessing a shift in trend from using conventional diagnostic tools towards using more advanced diagnostic methods that focus on producing accurate and consistent results during early stage of diseases. This has led to boost in demand for biomarkers which are minimally or non-invasive tools to detect diseases such as cancer at early stage. Moreover, growing usage of precision medicine should further boost the biomarkers market growth.

Apart from this, expediting growth in the healthcare IT industry and low costs of clinical trials in emerging countries has favored the entry of various new players in the market. A large chunk of funding is being invested in research and development for new product launches. For instance, in March 2018, Genomic Health, Inc. launched the Oncotype DX AR-V7 Nucleus Detect test. The AR-V7 protein is a prognostic and predictive biomarker. This test aids physicians in taking therapeutic decisions in patients suffering from metastatic castration-resistant prostate cancer (mCRPC) by accurately detecting a splice variant of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells (CTCs).

Recent Developments In May 2019, Qiagen announced the immediate launch of its first companion diagnostics assay therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) post U.S. FDA regulatory approval as a companion diagnostic to assist in diagnosing breast cancer patients that would be eligible for treatment with newly approved therapy PIQRAY (alpelisib) developed and marketed by Novartis.

Key Players in Biomarkers Market Some of the major players operating in the Global Biomarkers Market include Siemens Healthineers, Medtronic, F. Hoffman LA Roche Ltd., Abbott Laboratories Nexus-DX, Qiagen N.V., PerkinElmer, Inc., Lifesign LLC., Merck & Co, Inc., Bio-Rad Laboratories, EKF Diagnostics Holdings plc, Singulex, Inc., Signosis, Inc, and BioSims Technologies among others.

Global Biomarkers market is segmented on the basis of product, type, application, and disease indication. The Global Biomarkers Market by product includes consumables, services, and software, while based on type the industry is segmented into safety, efficacy, and validation. By application market segmentation includes diagnostics, drug development, personalized medicine, and disease risk assessment. Biomarkers market by disease indication comprises of cancer, cardiovascular diseases, neurological diseases, immunological diseases, and others.

Increasing incidence of cancer and growing precision medicine market are some of the pivotal factors boosting the Biomarkers market growth. Increasing incidence of cancer is one of the pivotal factors which is set to drive the growth of Biomarkers Market. According to World Health Organization (WHO) statistics, various types of cancer accounted for more than 9.5 million deaths in 2018 worldwide. Cancer biomarkers are released by cancer causing tumors that can be detected in blood stream and other tissues, thus helping in early clinical evaluation and deciding the course of treatment.

Moreover, the World Health Assembly has passed the resolution in 2017 for Cancer Prevention and Control. This integrated approach (WHA70.12) has recommended the governments and WHO to speed up action plans specified in the Global Action Plan and 2030 UN Agenda for Sustainable Development to reduce premature mortality from cancer. This has led to a boost in demand for early cancer screening tests and procedures. Increasing focus of research institutes to develop such biomarkers is likely to spur the global Biomarkers Market growth.

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Biomarkers Market.

Key Benefits for Biomarkers Market Reports Global market report covers in-depth historical and forecast analysis. Global market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. Global market report helps to identify opportunities in market place. Global market report covers extensive analysis of emerging trends and competitive landscape.

By Product:ConsumablesServicesSoftware

By Type: SafetyEfficacyValidation

By Application:DiagnosticsDrug DevelopmentPersonalized MedicineDisease Risk Assessment

By Disease Indication:CancerCardiovascular DiseasesNeurological DiseasesImmunological DiseasesOthers

By Region North Americao U.S.o Canadao Mexico Europeo UKo Franceo Germanyo Russiao Rest of Europe Asia-Pacifico Chinao South Koreao Indiao Japano Rest of Asia-Pacific LAMEAo Latin Americao Middle Easto Africa

North America grabbed the largest share in Biomarkers Market globally In 2018, North America accounted for the largest share in the global biomarkers market owing to increasing adoption of precision medicine and rising prevalence of cancer in the region. The largest share of the region is also attributed to the rise in number of cancer cases in the U.S. and launch of Precision Medicine Initiative (PMI) by the U.S. government in 2015. According to the National Cancer Institute statistics, more than 16.5 million cases of cancer were diagnosed in 2016 in the U.S, and this number is expected to reach to 19 million in 2024.

The increasing application of biomarkers in the field of precision medicine should also drive the market in this region. Identification of biomarkers is essential for the development of precision medicine. The U.S. precision medicine industry has been booming post the launch of Precision Medicine Initiative by the government in 2015. The initiative aimed at improving the treatment outcome by offering tailor made therapies to patients. This has spurred the development of novel treatments and drugs based on an individuals genetic profile and characteristics of tumor. The Asia Pacific Biomarkers market is set to showcase lucrative growth in the coming years due to vast patient pool, increasing awareness regarding early disease detection and rising healthcare expenditure in the emerging countries of India and China.

Biomarkers Market Key Players: Siemens Healthineers Medtronic F. Hoffman LA Roche Ltd. Abbott Laboratories Nexus-DX Qiagen N.V. PerkinElmer, Inc. Lifesign LLC. Merck & Co, Inc. Bio-Rad Laboratories EKF Diagnostics Holdings plc Others

This comprehensive report will provide: Enhance your strategic decision making Assist with your research, presentations and business plans Show which emerging market opportunities to focus on Increase your industry knowledge Keep you up-to-date with crucial market developments Allow you to develop informed growth strategies Build your technical insight Illustrate trends to exploit Strengthen your analysis of competitors Provide risk analysis, helping you avoid the pitfalls other companies could make Ultimately, help you to maximize profitability for your company.

Our Market Research Solution Provides You Answer to Below Mentioned Question: Which are the driving factors responsible for the growth of market? Which are the roadblock factors of this market? What are the new opportunities, by which market will grow in coming years? What are the trends of this market? Which are main factors responsible for new product launch? How big is the global & regional market in terms of revenue, sales and production? How far will the market grow in forecast period in terms of revenue, sales and production? Which region is dominating the global market and what are the market shares of each region in the overall market in 2017? How will each segment grow over the forecast period and how much revenue will these segment account for in 2025? Which region has more opportunities?

Table of Content1 Study Coverage1.1 Biomarkers Product1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered1.4 Market by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Executive Summary2.1 Global Biomarkers Market Size2.1.1 Global Biomarkers Revenue 2014-20252.1.2 Global Biomarkers Production 2014-20252.2 Biomarkers Growth Rate (CAGR) 2020-20252.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio2.3.2 Key Biomarkers Manufacturers2.3.2.1 Biomarkers Manufacturing Base Distribution, Headquarters2.3.2.2 Manufacturers Biomarkers Product Offered2.3.2.3 Date of Manufacturers Enter into Biomarkers Market2.4 Key Trends for Biomarkers Markets & Products

3 Market Size by Manufacturers3.1 Biomarkers Production by Manufacturers3.1.1 Biomarkers Production by Manufacturers3.1.2 Biomarkers Production Market Share by Manufacturers3.2 Biomarkers Revenue by Manufacturers3.2.1 Biomarkers Revenue by Manufacturers (2014-2020)3.2.2 Biomarkers Revenue Share by Manufacturers (2014-2020)3.3 Biomarkers Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans

4 Biomarkers Production by Regions4.1 Global Biomarkers Production by Regions4.1.1 Global Biomarkers Production Market Share by Regions4.1.2 Global Biomarkers Revenue Market Share by Regions4.2 North America4.2.1 North America Biomarkers Production4.2.2 North America Biomarkers Revenue4.2.3 Key Players in North America4.2.4 North America Biomarkers Import & Export4.3 Europe4.3.1 Europe Biomarkers Production4.3.2 Europe Biomarkers Revenue4.3.3 Key Players in Europe4.3.4 Europe Biomarkers Import & Export4.4 China4.4.1 China Biomarkers Production4.4.2 China Biomarkers Revenue4.4.3 Key Players in China4.4.4 China Biomarkers Import & Export4.5 Japan4.5.1 Japan Biomarkers Production4.5.2 Japan Biomarkers Revenue4.5.3 Key Players in Japan4.5.4 Japan Biomarkers Import & Export

5 Biomarkers Consumption by Regions5.1 Global Biomarkers Consumption by Regions5.1.1 Global Biomarkers Consumption by Regions5.1.2 Global Biomarkers Consumption Market Share by Regions5.2 North America5.2.1 North America Biomarkers Consumption by Application5.2.2 North America Biomarkers Consumption by Countries5.2.3 United States5.2.4 Canada5.2.5 Mexico5.3 Europe5.3.1 Europe Biomarkers Consumption by Application5.3.2 Europe Biomarkers Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 UK5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Biomarkers Consumption by Application5.4.2 Asia Pacific Biomarkers Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Indonesia5.4.9 Thailand5.4.10 Malaysia5.4.11 Philippines

About Us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Blog: https://businessstatsnews.com

Blog: http://www.dailyindustrywatch.com

Blog: https://marketsize.biz

Blog: https://technologyindustrynews.com

Blog: https://marketstatsreport.com

Top Trending Reports:

https://www.marketwatch.com/press-release/tart-cherry-market-size-share-from-2020-to-2025-growth-forecast-analysis-by-manufacturers-type-and-application-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/global-gaming-hardware-market-2020-industry-analysis-by-share-trends-growth-factors-cagr-status-growth-opportunities-segmentation-and-forecast-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/obsessive-compulsive-disorder-ocd-market-2020-growth-analysis-share-demand-types-top-key-players-and-forecast-to-2025-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/geocells-market-size-revenue-analysis-growth-opportunities-and-forecast-2025-strata-systems-inc-wrekin-products-ltd-armtec-infrastructure-inc-maccaferri-spa-ace-2020-08-13?tesla=y

https://www.marketwatch.com/press-release/at-1150-cagr-biophotonics-market-size-to-surpass-usd-8908-billion-by-2025-forecast-by-applications-dynamics-development-status-and-outlook-2025-2020-08-13?tesla=y

Read the original here:
Outlook on the Worldwide Biomarkers Industry to 2025 Scientect - Scientect

Every successful medicinal activity requires mass production of quality stem cells. This is what avails regenerative medicine to the public the need occasioned the founding of Cellect Biotechnology Ltd ADR (NASDAQ:APOP). In 2011. The companys vision was to bring to reality regenerative treatments, which would accelerate the production of stem cell-based treatments.

Cellect has spent 15 years in research, thanks to its ApoGraft methodology, which is long-sought-after because it engages an inexpensive process. This is what has birthed seven families of patents. The company just received a pivotal patent for Stem Cells Activation from the European Patent Office. This patent, which will expire on October 7, 2034, is the most significant event for the company seeking to strengthen its Intellectual Property (IP) portfolio.

Over the past few years, the need to strengthen its IP has been a core component of the companys business strategy. According to the CEO Dr. Shai Yarkoni, they wanted to tap into the clinical and economic benefits, which come with the patent. The primary benefit and, as the company has demonstrated previously, is the increased safety and efficacy of the cell product. This is enhanced by the development of a robust and user-friendly process.

While the extensive issued patents cover the accurate elimination (negative selection) of the mature cells and therefor enables SAFETY, this patent covers the increased ACTIVITY (positive selection=efficacy) of the regenerative capacity of the stem and progenitor cells Yarkoni explained.

Cellect Biotechnology has 65 patents in nine patent families. Out of these, 45 of them have been allowed patent, 18 are waiting for examination while the remaining two are the Patent Cooperation Treaty (PCT) applications. The Biotech aim is to expand and protect global IP. This will provide researchers and clinical community tools to isolate stem cells in quantity and quality rapidly. The final results will automatically be a wide variety of applications in regenerative medicine.

Meanwhile, the company has also been consulting and discussing widely with global leaders. Before long, it will be able to take control of innovation in the development of cell therapies.

See the original post:
Cellect Biotechnology Ltd ADR (NASDAQ:APOP) Receives an Approval of a Pivotal Patent for Stem Cells Activation from the European Patent Office - BP...

The Covid-19 pandemic is one of the greatest challenges modern medicine has ever faced. Doctors and scientists are scrambling to find treatments and drugs that can save the lives of infected people and perhaps even prevent them from getting sick in the first place.

Below is an updated list of 20 of the most-talked-about treatments for the coronavirus. While some are accumulating evidence that theyre effective, most are still at early stages of research. We also included a warning about a few that are just bunk.

We are following 20 coronavirus treatments for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

Tentative or

mixed evidence

We are following 20 coronavirus treatments

for effectiveness and safety:

There is no cure yet for Covid-19. And even the most promising treatments to date only help certain groups of patients and await validation from further trials. The F.D.A. has not fully licensed any treatment specifically for the coronavirus. Although it has granted emergency use authorization to some treatments, their effectiveness against Covid-19 has yet to be demonstrated in large-scale, randomized clinical trials.

This list provides a snapshot of the latest research on the coronavirus, but does not constitute medical endorsements. Always consult your doctor about treatments for Covid-19.

New additions and recent updates:

Added ivermectin, a drug typically used against parasitic worms that is being increasingly prescribed in Latin America. Aug. 10

Updated descriptions for several treatments. Aug. 10

We will update and expand the list as new evidence emerges. For details on evaluating treatments, see the N.I.H. Covid-19 Treatment Guidelines. For the current status of vaccine development, see our Coronavirus Vaccine Tracker.

WIDELY USED: These treatments have been used widely by doctors and nurses to treat patients hospitalized for diseases that affect the respiratory system, including Covid-19.

PROMISING EVIDENCE: Early evidence from studies on patients suggests effectiveness, but more research is needed. This category includes treatments that have shown improvements in morbidity, mortality and recovery in at least one randomized controlled trial, in which some people get a treatment and others get a placebo.

TENTATIVE OR MIXED EVIDENCE: Some treatments show promising results in cells or animals, which need to be confirmed in people. Others have yielded encouraging results in retrospective studies in humans, which look at existing datasets rather than starting a new trial. Some treatments have produced different results in different experiments, raising the need for larger, more rigorously designed studies to clear up the confusion.

NOT PROMISING: Early evidence suggests that these treatments do not work.

PSEUDOSCIENCE OR FRAUD: These are not treatments that researchers have ever considered using for Covid-19. Experts have warned against trying them, because they do not help against the disease and can instead be dangerous. Some people have even been arrested for their false promises of a Covid-19 cure.

EVIDENCE IN CELLS, ANIMALS or HUMANS: These labels indicate where the evidence for a treatment comes from. Researchers often start out with experiments on cells and then move onto animals. Many of those animal experiments often fail; if they dont, researchers may consider moving on to research on humans, such as retrospective studies or randomized clinical trials. In some cases, scientists are testing out treatments that were developed for other diseases, allowing them to move directly to human trials for Covid-19.

All treatmentsWidely usedPromisingTentative or mixedNot promisingPseudoscience

Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. Scientists are searching for antivirals that work against the new coronavirus.

PROMISING EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSEMERGENCY USE AUTHORIZATIONRemdesivirRemdesivir, made by Gilead Sciences, was the first drug to get emergency authorization from the F.D.A. for use on Covid-19. It stops viruses from replicating by inserting itself into new viral genes. Remdesivir was originally tested as an antiviral against Ebola and Hepatitis C, only to deliver lackluster results. But preliminary data from trials that began this spring suggested the drug can reduce the recovery time of people hospitalized with Covid-19 from 15 to 11 days. (The study defined recovery as either discharge from the hospital or hospitalization for infection-control purposes only.) These early results did not show any effect on mortality, though retrospective data released in July hints that the drug might reduce death rates among those who are very ill.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSFavipiravirOriginally designed to beat back influenza, favipiravir blocks a viruss ability to copy its genetic material. A small study in March indicated the drug might help purge the coronavirus from the airway, but results from larger, well-designed clinical trials are still pending.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMK-4482Another antiviral originally designed to fight the flu, MK-4482 (previously known as EIDD-2801) has had promising results against the new coronavirus in studies in cells and on animals. Merck, which has been running clinical trials on the drug this summer, has announced it will launch a large Phase III trial in September.Updated Aug. 6

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS Recombinant ACE-2To enter cells, the coronavirus must first unlock them a feat it accomplishes by latching onto a human protein called ACE-2. Scientists have created artificial ACE-2 proteins which might be able to act as decoys, luring the coronavirus away from vulnerable cells. Recombinant ACE-2 proteins have shown promising results in experiments on cells, but not yet in animals or people.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS IvermectinFor decades, ivermectin has served as a potent drug to treat parasitic worms. Doctors use it against river blindness and other diseases, while veterinarians give dogs a different formulation to cure heartworm. Studies on cells have suggested ivermectin might also kill viruses. But scientists have yet to find evidence in animal studies or human trials that it can treat viral diseases. As a result, Ivermectin is not approved to use as an antiviral.

In April, Australian researchers reported that the drug blocked coronaviruses in cell cultures, but they used a dosage that was so high it might have dangerous side effects in people. The FDA immediately issued a warning against taking pet medications to treat or prevent Covid-19. These animal drugs can cause serious harm in people, the agency warned.

Since then a number of clinical trials have been launched to see if a safe dose of ivermectin can fight Covid-19. In Singapore, for example, the National University Hospital is running a 5,000-person trial to see if it can prevent people from getting infected. As of now, theres no firm evidence that it works. Nevertheless ivermectin is being prescribed increasingly often in Latin America, much to the distress of disease experts.Updated Aug. 10

NOT PROMISING EVIDENCE IN CELLS AND HUMANS Lopinavir and ritonavirTwenty years ago, the F.D.A. approved this combination of drugs to treat H.I.V. Recently, researchers tried them out on the new coronavirus and found that they stopped the virus from replicating. But clinical trials in patients proved disappointing. In early July, the World Health Organization suspended trials on patients hospitalized for Covid-19. They didnt rule out studies to see if the drugs could help patients not sick enough to be hospitalized, or to prevent people exposed to the new coronavirus from falling ill. The drug could also still have a role to play in certain combination treatments.

NOT PROMISING EVIDENCE IN CELLS, ANIMALS AND HUMANSHydroxychloroquine and chloroquineGerman chemists synthesized chloroquine in the 1930s as a drug against malaria. A less toxic version, called hydroxychloroquine, was invented in 1946, and later was approved for other diseases such as lupus and rheumatoid arthritis. At the start of the Covid-19 pandemic, researchers discovered that both drugs could stop the coronavirus from replicating in cells.

Since then, theyve had a tumultuous ride. A few small studies on patients offered some hope that hydroxychloroquine could treat Covid-19. The World Health Organization launched a randomized clinical trial in March to see if it was indeed safe and effective for Covid-19, as did Novartis and a number of universities. Meanwhile, President Trump repeatedly promoted hydroxychloroquine at press conferences, touting it as a game changer, and even took it himself. The F.D.A. temporarily granted hydroxychloroquine emergency authorization for use in Covid-19 patients which a whistleblower later claimed was the result of political pressure. In the wake of the drugs newfound publicity, demand spiked, resulting in shortages for people who rely on hydroxychloroquine as a treatment for other diseases.

But more detailed studies proved disappointing. A study on monkeys found that hydroxychloroquine didnt prevent the animals from getting infected and didnt clear the virus once they got sick. Randomized clinical trials found that hydroxychloroquine didnt help people with Covid-19 get better or prevent healthy people from contracting the coronavirus. Another randomized clinical trial found that giving hydroxychloroquine to people right after being diagnosed with Covid-19 didnt reduce the severity of their disease. (One large-scale study that concluded the drug was harmful as well was later retracted.) The World Health Organization, the National Institutes of Health and Novartis have since halted trials investigating hydroxychloroquine as a treatment for Covid-19, and the F.D.A. revoked its emergency approval. The F.D.A. now warns that the drug can cause a host of serious side effects to the heart and other organs when used to treat Covid-19.

In July, researchers at Henry Ford hospital in Detroit published a study finding that hydroxychloroquine was associated with a reduction in mortality in Covid-19 patients. President Trump praised the study on Twitter, but experts raised doubts about it. The study was not a randomized controlled trial, in which some people got a placebo instead of hydroxychloroquine. The studys results might not be due to the drug killing the virus. Instead, doctors may have given the drug to people who were less sick, and thus more likely to recover anyway.

Despite negative results, a number of hydroxychloroquine trials have continued, although most are small, testing a few dozen or a few hundred patients. A recent analysis by STAT and Applied XL found more than 180 ongoing clinical trials testing hydroxychloroquine or chloroquine, for treating or preventing Covid-19. Although its clear the drugs are no panacea, its theoretically possible they could provide some benefit in combination with other treatments, or when given in early stages of the disease. Only well-designed trials can determine if thats the case.Updated Aug. 10

Most people who get Covid-19 successfully fight off the virus with a strong immune response. Drugs might help people who cant mount an adequate defense.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS AND HUMANS Convalescent plasmaA century ago, doctors filtered plasma from the blood of recovered flu patients. So-called convalescent plasma, rich with antibodies, helped people sick with flu fight their illness. Now researchers are trying out this strategy on Covid-19. In May, the F.D.A. designated convalescent plasma an investigational product. That means that despite not yet being shown as safe and effective, plasma can be used in clinical trials and given to some patients who are seriously ill with Covid-19. Tens of thousands of patients in the U.S. have received plasma through a program launched by the Mayo Clinic and the federal government.

The Trump administration has praised convalescent plasma, despite the lack of evidence yet that it works. The first wave of trials have been small and the results have been mixed. Large randomized clinical trials are underway, but theyve struggled to enroll enough participants, some of whom worry they will receive a placebo instead of the treatment itself.

Experts say that its vital to complete these trials to determine if convalescent plasma is safe and effective. If these trials are successful, it could serve as an important stopgap measure until more potent therapies become widely available.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSMonoclonal antibodiesConvalescent plasma from people who recover from Covid-19 contains a mix of different antibodies. Some of the molecules can attack the coronavirus, but many are directed at other pathogens. Researchers have sifted through this slurry to find the most potent antibodies against Covid-19. They have then manufactured synthetic copies of these molecules, known as monoclonal antibodies. Researchers have begun investigating them as a treatment for Covid-19, either individually or in cocktails.

Monoclonal antibodies were first developed as a therapy in the 1970s, and since then the F.D.A. has approved them for 79 diseases, ranging from cancer to AIDS. Since the start of the pandemic, researchers have found dozens of monoclonal antibodies that show promise against Covid-19 in preclinical studies on cells and animals. Companies like Eli Lilly and Regeneron recently began clinical trials studying monoclonal antibodies. Several other firms, as well as teams at universities, are slated to enter the race soon as well.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN CELLS, ANIMALS AND HUMANSInterferonsInterferons are molecules our cells naturally produce in response to viruses. They have profound effects on the immune system, rousing it to attack the invaders, while also reining it in to avoid damaging the bodys own tissues. Injecting synthetic interferons is now a standard treatment for a number of immune disorders. Rebif, for example, is prescribed for multiple sclerosis.

As part of its strategy to attack our bodies, the coronavirus appears to tamp down interferon. That finding has encouraged researchers to see whether a boost of interferon might help people weather Covid-19, particularly early in infection. Early studies, including experiments in cells and mice, have yielded encouraging results that have led to clinical trials.

An open-label study in China suggested that the molecules could help prevent healthy people from getting infected. On July 20, the British pharmaceutical company Synairgen announced that an inhaled form of interferon called SNG001 lowered the risk of severe Covid-19 in infected patients in a small clinical trial. The full data have not yet been released to the public, or published in a scientific journal. On August 6, the National Institute of Allergy and Infectious Diseases launched a Phase III trial on a combination of Rebif and the antiviral remdesivir, with results expected by fall 2020.Updated Aug. 10

The most severe symptoms of Covid-19 are the result of the immune systems overreaction to the virus. Scientists are testing drugs that can rein in its attack.

PROMISING EVIDENCE EVIDENCE IN HUMANS DexamethasoneThis cheap and widely available steroid blunts many types of immune responses. Doctors have long used it to treat allergies, asthma and inflammation. In June, it became the first drug shown to reduce Covid-19 deaths. That study of more than 6,000 people, which in July was published in the New England Journal of Medicine, found that dexamethasone reduced deaths by one-third in patients on ventilators, and by one-fifth in patients on oxygen. It may be less likely to help and may even harm patients who are at an earlier stage of Covid-19 infections, however. In its Covid-19 treatment guidelines, the National Institutes of Health recommends only using dexamethasone in patients with COVID-19 who are on a ventilator or are receiving supplemental oxygen.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Cytokine InhibitorsThe body produces signaling molecules called cytokines to fight off diseases. But manufactured in excess, cytokines can trigger the immune system to wildly overreact to infections, in a process sometimes called a cytokine storm. Researchers have created a number of drugs to halt cytokine storms, and they have proven effective against arthritis and other inflammatory disorders. Some turn off the supply of molecules that launch the production of the cytokines themselves. Others block the receptors on immune cells to which cytokines would normally bind. A few block the cellular messages they send. Depending on how the drugs are formulated, they can block one cytokine at a time, or muffle signals from several at once.

Against the coronavirus, several of these drugs have offered modest help in some trials, but faltered in others. Drug companies Regeneron and Roche drug both recently announced that two drugs called sarilumab and tocilizumab, which both target the cytokine IL-6, did not appear to benefit patients in Phase 3 clinical trials. Many other trials remain underway, several of which combine cytokine inhibitors with other treatments.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS EMERGENCY USE AUTHORIZATIONBlood filtration systemsThe F.D.A. has granted emergency use authorization to several devices that filter cytokines from the blood in an attempt to cool cytokine storms. One machine, called Cytosorb, can reportedly purify a patients entire blood supply about 70 times in a 24-hour period. A small study in March suggested that Cytosorb had helped dozens of severely ill Covid-19 patients in Europe and China, but it was not a randomized clinical trial that could conclusively demonstrate it was effective. A number of studies on blood filtration systems are underway, but experts caution that these devices carry some risks. For example, such filters could remove beneficial components of blood as well, such as vitamins or medications.Updated Aug. 10

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS Stem cellsCertain kinds of stem cells can secrete anti-inflammatory molecules. Over the years, researchers have tried to use them as a treatment for cytokine storms, and now dozens of clinical trials are under way to see if they can help patients with Covid-19. But these stem cell treatments havent worked well in the past, and its not clear yet if theyll work against the coronavirus.

Doctors and nurses often administer other supportive treatments to help patients with Covid-19.

WIDELY USEDProne positioningThe simple act of flipping Covid-19 patients onto their bellies opens up the lungs. The maneuver has become commonplace in hospitals around the world since the start of the pandemic. It might help some individuals avoid the need for ventilators entirely. The treatments benefits continue to be tested in a range of clinical trials.

WIDELY USEDEMERGENCY USE AUTHORIZATIONVentilators and other respiratory support devicesDevices that help people breathe are an essential tool in the fight against deadly respiratory illnesses. Some patients do well if they get an extra supply of oxygen through the nose or via a mask connected to an oxygen machine. Patients in severe respiratory distress may need to have a ventilator breathe for them until their lungs heal. Doctors are divided about how long to treat patients with noninvasive oxygen before deciding whether or not they need a ventilator. Not all Covid-19 patients who go on ventilators survive, but the devices are thought to be lifesaving in many cases.

TENTATIVE OR MIXED EVIDENCE EVIDENCE IN HUMANS AnticoagulantsThe coronavirus can invade cells in the lining of blood vessels, leading to tiny clots that can cause strokes and other serious harm. Anticoagulants are commonly used for other conditions, such as heart disease, to slow the formation of clots, and doctors sometimes use them on patients with Covid-19 who have clots. Many clinical trials teasing out this relationship are now underway. Some of these trials are looking at whether giving anticoagulants before any sign of clotting is beneficial.

False claims about Covid-19 cures abound. The F.D.A. maintains a list of more than 80 fraudulent Covid-19 products, and the W.H.O. debunks many myths about the disease.

WARNING: DO NOT DO THISDrinking or injecting bleach and disinfectantsIn April, President Trump suggested that disinfectants such as alcohol or bleach might be effective against the coronavirus if directly injected into the body. His comments were immediately refuted by health professionals and researchers around the world as well as the makers of Lysol and Clorox. Ingesting disinfectant would not only be ineffective against the virus, but also hazardous possibly even deadly. In July, Federal prosecutors charged four Florida men with marketing bleach as a cure for COVID-19.

WARNING: NO EVIDENCEUV lightPresident Trump also speculated about hitting the body with ultraviolet or just very powerful light. Researchers have used UV light to sterilize surfaces, including killing viruses, in carefully managed laboratories. But UV light would not be able to purge the virus from within a sick persons body. This kind of radiation can also damage the skin. Most skin cancers are a result of exposure to the UV rays naturally present in sunlight.

WARNING: NO EVIDENCESilverThe F.D.A. has threatened legal action against a host of people claiming silver-based products are safe and effective against Covid-19 including televangelist Jim Bakker and InfoWars host Alex Jones. Several metals do have natural antimicrobial properties. But products made from them have not been shown to prevent or treat the coronavirus.

Note: After additional discussions with experts we have adjusted several labels on the tracker. The Strong evidence label has been removed until further research identifies treatments that consistently benefit groups of patients infected by the coronavirus. In its place, Promising evidence will be used for drugs such as remdesivir and dexamethasone that have shown promise in at least one randomized controlled trial, and Widely used for treatments such as proning and ventilators that are often used with severely ill patients, including those with Covid-19. And we may reintroduce the Ineffective label when ongoing clinical trials repeatedly end with disappointing results.

Sources: National Library of Medicine; National Institutes of Health; William Amarquaye, University of South Florida; Paul Bieniasz, Rockefeller University; Jeremy Faust, Brigham & Womens Hospital; Matt Frieman, University of Maryland School of Medicine; Noah Haber, Stanford University; Swapnil Hiremath, University of Ottawa; Akiko Iwasaki, Yale University; Paul Knoepfler, University of California, Davis; Elena Massarotti, Brigham and Womens Hospital; John Moore and Douglas Nixon, Weill Cornell Medical College; Erica Ollman Saphire, La Jolla Institute for Immunology; Regina Rabinovich, Harvard T.H. Chan School of Public Health; Ilan Schwartz, University of Alberta; Phyllis Tien, University of California, San Francisco.

See the original post here:
Coronavirus Drug and Treatment Tracker - The New York Times